TAIPEI, Dec. 30, 2025 /PRNewswire/ — TOMO YUME Group today announced that its subsidiary, Sparkling Sciences, a leader in exosome research and development, has TAIPEI, Dec. 30, 2025 /PRNewswire/ — TOMO YUME Group today announced that its subsidiary, Sparkling Sciences, a leader in exosome research and development, has

TOMO YUME Group Subsidiary SPARKLING SCIENCES Achieves Dual U.S. INCI Certifications, Accelerating Global Expansion of Advanced Exosome Ingredients

TAIPEI, Dec. 30, 2025 /PRNewswire/ — TOMO YUME Group today announced that its subsidiary, Sparkling Sciences, a leader in exosome research and development, has successfully obtained dual certifications from the U.S. International Nomenclature Cosmetic Ingredient (INCI) system. This milestone validates the company’s proprietary R&D capabilities and establishes a regulatory foundation for its global expansion into high-performance scalp, hair, and skincare markets.

The certification covers two proprietary ingredients derived from Sparkling Sciences’ advanced biotechnology, which integrates clinical-grade purification with freeze-drying processes:

  • Human Hair Follicle Dermal Papilla Cell Exosomes (INCI ID: 40983) A premium biotechnology ingredient designed for advanced scalp care and hair root conditioning.
  • Organic Rice Bran-Derived Vesicles (INCI ID: 40956) A versatile botanical ingredient proven to enhance moisturization, skin texture, and hair volume. It has already been adopted in commercial formulations.

“The acquisition of U.S. INCI certification is a pivotal moment in our R&D journey, signaling international recognition of our technical precision,” said Dr. Fang-Chen Kao, CEO of Sparkling Sciences. “Specifically, our Dermal Papilla Cell Exosomes demonstrate our strength in developing next-generation scalp solutions. Guided by our philosophy of ‘From Science to Beauty and Health,’ we are rapidly expanding applications across both human and animal healthcare sectors.”

Beyond human cosmetics, Sparkling Sciences has achieved mass production of highly stable freeze-dried exosome powders for the pet healthcare market, receiving strong uptake from industry partners.

Expanding Production Capabilities: To meet growing global demand, Sparkling Sciences is developing a new state-of-the-art R&D and manufacturing facility, scheduled for completion in 2026. The facility will launch with GTP (Good Tissue Practice) validation to ensure traceability and safety, followed by a phased implementation of GMP (Good Manufacturing Practice) standards. This expansion will significantly boost production capacity for high-purity exosome ingredients, positioning TOMO YUME Group at the forefront of the global biotech beauty industry.

Company Profile

Company Name: Sparkling Sciences
Headquarters: Taipei & Taichung, Taiwan
CEO: Dr. Fang-Chen Kao
Business Scope: Research, development, and manufacturing of exosome ingredients; planning and sales of skincare and healthcare products
Affiliated Companies: TOMO YUME Group; ArcBio Co., Ltd. (Tokyo)
Websites:
https://www.sparklingsci.com/
https://www.tomoyume.com/
https://www.arcbiojp.com/

Media Contact:
Johnson Chen
+886939631095
406887@email4pr.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tomo-yume-group-subsidiary-sparkling-sciences-achieves-dual-us-inci-certifications-accelerating-global-expansion-of-advanced-exosome-ingredients-302650293.html

SOURCE Sparkling Sciences

Market Opportunity
Union Logo
Union Price(U)
$0.003036
$0.003036$0.003036
-1.26%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.